TREX WIND-DOWN, INC.
TMBR evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for TMBR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2023.
Tracking 2 pipeline candidates for TREX WIND-DOWN, INC..
Run TREX WIND-DOWN, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available TREX WIND-DOWN, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
2.9 months
OCF -$3M · Net income -$4M
Lead: Phase 3
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Frequently asked questions
What is TREX WIND-DOWN, INC.'s lead drug candidate?
TREX WIND-DOWN, INC.'s most advanced tracked candidate is tmb-001 (Phase 3) for Congenital ichthyosis (CI), including X-linked recessive CI (XLRI) and autosomal recessive CI (ARCI).
What therapeutic areas does TREX WIND-DOWN, INC. focus on?
TREX WIND-DOWN, INC. develops therapies across Immunology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.